|
|
他汀类药物在降低残余胆固醇中的作用研究进展
|
Abstract:
该文综述了他汀类药物在降低残余胆固醇中的作用研究进展，介绍了不同种类的他汀类药物对血清残余胆固醇的影响。阿托伐他汀、瑞舒伐他汀、辛伐他汀、匹伐他汀及普伐他汀均可显著降低血清残余胆固醇，但氟伐他汀的疗效尚不明确。他汀类药物与烟酸、依折麦布等非他汀类调脂药物中的一种联合用药，可加强疗效。他汀类药物与鱼油联合使用，同样可以增强疗效。
The research progress of statins in reducing remnant cholesterol was reviewed. The impacts of dif-ferent doses of statins on remnant cholesterol were introduced. Residual cholesterol was signifi-cantly reduced with atorvastatin, rosuvastatin, simvastatin, pitavastatin and pravastatin, but the efficacy of fluvastatin is indeterminate. Statins in combination with non-statin ester regulating drugs such as niacin or ezetimibe enhances efficacy. A combination of statins with fish oil also en-hances the efficacy.
| [1] | Ferri, N. and Corsini, A. (2020) Clinical Pharmacology of Statins: An Update. Current Atherosclerosis Reports, 22, Article No. 26. https://doi.org/10.1007/s11883-020-00844-w |
| [2] | Vallejo-Vaz, A.J., Fayyad, R., Boekholdt, S.M., et al. (2018) Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events among Patients Receiving Statin Therapy in the TNT Trial. Circulation, 138, 770-781.
https://doi.org/10.1161/CIRCULATIONAHA.117.032318 |
| [3] | Elshazly, M.B., Mani, P., Nissen, S., et al. (2020) Remnant Cholesterol, Coronary Atheroma Progression and Clinical Events in Statin-Treated Patients with Coronary Ar-tery Disease. European Journal of Preventive Cardiology, 27, 1091-1100. https://doi.org/10.1177/2047487319887578 |
| [4] | Varbo, A., Benn, M., Tybjaerg-Hansen, A., et al. (2013) Remnant Cholesterol as a Causal Risk Factor for Ischemic Heart Disease. Journal of the American College of Cardiology, 61, 427-436.
https://doi.org/10.1016/j.jacc.2012.08.1026 |
| [5] | Quispe, R., Martin, S.S., Michos, E.D., et al. (2021) Remnant Cholesterol Predicts Cardiovascular Disease beyond LDL and ApoB: A Primary Prevention Study. European Heart Journal, 42, 4324-4332.
https://doi.org/10.1093/eurheartj/ehab432 |
| [6] | 陈焱, 赵昕, 艾冠男, 等. 高血压前期患者残余胆固醇与冠状动脉狭窄严重程度的相关性[J]. 中国动脉硬化杂志, 2021, 29(12): 1047-1052. |
| [7] | Stein, D.T., Devaraj, S., Balis, D., Adams-Huet, B. and Jialal, I. (2001) Effect of Statin Therapy on Remnant Lipoprotein Cholesterol Levels in Patients with Combined Hyperlipidemia. Arteriosclerosis, Thrombosis, and Vascular Biology, 21, 2026-2031. https://doi.org/10.1161/hq1201.100259 |
| [8] | Dane-Stewart, C.A., Watts, G.F., Pal, S., et al. (2003) Effect of Atorvastatin on Apolipoprotein B48 Metabolism and Low-Density Lipoprotein Receptor Activity in Normolipidemic Pa-tients with Coronary Artery Disease. Metabolism: Clinical and Experimental, 52, 1279-1286. https://doi.org/10.1016/S0026-0495(03)00281-6 |
| [9] | Schaefer, E.J., Mcnamara, J.R., Tayler, T., et al. (2002) Ef-fects of atorvastatin on Fasting and Postprandial Lipoprotein Subclasses in Coronary Heart Disease Patients versus Con-trol Subjects. American Journal of Cardiology, 90, 689-696.
https://doi.org/10.1016/S0002-9149(02)02591-2 |
| [10] | Caslake, M.J., Stewart, G., Day, S.P., et al. (2003) Pheno-type-Dependent and -Independent Actions of Rosuvastatin on Atherogenic Lipoprotein Subfractions in Hyperlipidaemia. Atherosclerosis, 171, 245-253.
https://doi.org/10.1016/j.atherosclerosis.2003.08.025 |
| [11] | Blom, D.J., Marais, A.D., Retterstol, K., et al. (2008) Rosuvastatin Reduces Non-High-Density Lipoprotein Cholesterol and Lipoprotein Remnants in Patients with Dysbetali-poproteinemia (Fredrickson Type III Hyperlipoproteinemia). Journal of Clinical Lipidology, 2, 418-425. https://doi.org/10.1016/j.jacl.2008.10.002 |
| [12] | De SauvageNolting, P.R., Twickler, M.B., Dallinga-Thie, G.M., et al. (2002) Elevated Remnant-Like Particles in Heterozygous Familial Hypercholesterolemia and Response to Statin Therapy. Circulation, 106, 788-792.
https://doi.org/10.1161/01.CIR.0000025586.89221.4B |
| [13] | 王慧, 孔令杰, 朱立勤. 普伐他汀的药代动力学及影响因素[J]. 天津药学, 2017, 29(5): 55-58. |
| [14] | Sano, K., Nakamura, T., Hirano, M., et al. (2010) Comparative Study of Bezafibrate and Pravastatin in Patients with Coronary Artery Disease and High Levels of Remnant Lipoprotein. Circulation Journal, 74, 1644-1650.
https://doi.org/10.1253/circj.CJ-10-0079 |
| [15] | Chapman, M.J., Orsoni, A., Robillard, P., et al. (2018) Duality of Statin Action on Lipoprotein Subpopulations in the Mixed Dyslipidemia of Metabolic Syndrome: Quantity vs Quality over Time and Implication of CETP. Journal of Clinical Lipidology, 12, 784-800.E4. https://doi.org/10.1016/j.jacl.2018.02.001 |
| [16] | Kawagoe, Y., Hattori, Y., Nakano, A., et al. (2011) Comparative Study between High-Dose Fluvastatin and Low-Dose Fluvastatin and Ezetimibe with Regard to the Effect on Endothelial Function in Diabetic Patients. Endocrine Journal, 58, 171-175. https://doi.org/10.1507/endocrj.K10E-289 |
| [17] | Schaefer, E.J., Mcnamara, J.R., Tayler, T., et al. (2004) Compari-sons of Effects of Statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) on Fasting and Postprandial Lipoproteins in Patients with Coronary Heart Disease versus Control Subjects. American Journal of Cardiology, 93, 31-39. https://doi.org/10.1016/j.amjcard.2003.09.008 |
| [18] | Tomassini, J.E., Mazzone, T., Goldberg, R.B., et al. (2009) Effect of Ezetimibe/Simvastatin Compared with Atorvastatin on Lipoprotein Subclasses in Patients with Type 2 Diabetes and Hypercholesterolaemia. Diabetes, Obesity & Metabolism, 11, 855-864. https://doi.org/10.1111/j.1463-1326.2009.01061.x |
| [19] | Toth, P.P., Bays, H.E., Brown, W.V., et al. (2019) Com-paring Remnant Lipoprotein Cholesterol Measurement Methods to Evaluate Efficacy of Ezetimibe/Statin vs Statin Thera-py. Journal of Clinical Lipidology, 13, 997-1007.E8.
https://doi.org/10.1016/j.jacl.2019.09.001 |
| [20] | El-Tamalawy, M.M., Ibrahim, O.M., Hassan, T.M. and El-Barbari, A.A. (2018) Effect of Combination Therapy of Ezetimibe and Atorvastatin on Remnant Lipoprotein versus Double Atorvastatin Dose in Egyptian Diabetic Patients. The Journal of Clinical Pharmacology, 58, 34-41. https://doi.org/10.1002/jcph.976 |
| [21] | 中国血脂管理指南修订联合专家委员会. 中国血脂管理指南(2023年) [J]. 中华心血管病杂志, 2023, 51(3): 221-255. |
| [22] | Nakamura, T., Hirano, M., Kitta, Y., et al. (2012) A Comparison of the Effi-cacy of Combined Ezetimibe and Statin Therapy with Doubling of Statin Dose in Patients with Remnant Lipoproteinemia on Previous Statin Therapy. Journal of Cardiology, 60, 12-17. https://doi.org/10.1016/j.jjcc.2012.02.005 |
| [23] | Tobaru, T., Seki, A., Asano, R., Sumiyoshi, T. and Hagiwara, N. (2013) Lipid-Lowering and Anti-Inflammatory Effect of Ezetimibe in Hyperlipidemic Patients with Coronary Artery Disease. Heart Vessels, 28, 39-45.
https://doi.org/10.1007/s00380-012-0243-8 |
| [24] | Torimoto, K., Okada, Y., Mori, H., et al. (2013) Efficacy of Com-bination of Ezetimibe 10 mg and Rosuvastatin 2.5 mg versus Rosuvastatin 5 mg Monotherapy for Hypercholesterolemia in Patients with Type 2 Diabetes. Lipids in Health and Disease, 12, Article No. 137. https://doi.org/10.1186/1476-511X-12-137 |
| [25] | Sakamoto, K., Kawamura, M., Kohro, T., et al. (2015) Effect of Ezetimibe on LDL-C Lowering and Atherogenic Lipoprotein Profiles in Type 2 Diabetic Patients Poorly Controlled by Statins. PLOS ONE, 10, e0138332.
https://doi.org/10.1371/journal.pone.0138332 |
| [26] | Varbo, A. and Nordestgaard, B.G. (2017) Remnant Lipoproteins. Current Opinion in Lipidology, 28, 300-307.
https://doi.org/10.1097/MOL.0000000000000429 |
| [27] | Sandesara, P.B., Virani, S.S., Fazio, S. and Shapiro, M.D. (2019) The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk. En-docrine Reviews, 40, 537-557.
https://doi.org/10.1210/er.2018-00184 |
| [28] | Uemura, Y., Watarai, M., Ishii, H., et al. (2012) Atorvastatin 10 mg plus Ezetimibe 10mg Compared with Atorvastatin 20mg: Impact on the Lipid Profile in Japanese Patients with Ab-normal Glucose Tolerance and Coronary Artery Disease. Journal of Cardiology, 59, 50-56. https://doi.org/10.1016/j.jjcc.2011.09.001 |
| [29] | Knopp, R.H., Retzlaff, B.M., Fish, B., et al. (2009) The SLIM Study: Slo-Niacin and Atorvastatin Treatment of Lipoproteins and Inflammatory Markers in Combined Hyperlipidemia. Journal of Clinical Lipidology, 3, 167-178.
https://doi.org/10.1016/j.jacl.2009.04.052 |
| [30] | Nakajima, K., Nakano, T. and Tanaka, A. (2006) The Oxidative Modi-fication Hypothesis of Atherosclerosis: The Comparison of Atherogenic Effects on Oxidized LDL and Remnant Lipo-proteins in Plasma. Clinica Chimica Acta, 367, 36-47.
https://doi.org/10.1016/j.cca.2005.12.013 |
| [31] | Nordestgaard, B.G., Langsted, A., Mora, S., et al. (2016) Fasting Is Not Routinely Required for Determination of a Lipid Profile: Clinical and Laboratory Implications Including Flagging at Desirable Concentration Cut-Points—A Joint Consensus Statement from the European Atherosclerosis Society and Eu-ropean Federation of Clinical Chemistry and Laboratory Medicine. European Heart Journal, 37, 1944-1958. https://doi.org/10.1093/eurheartj/ehw152 |
| [32] | Chan, D.C., Watts, G.F., Mori, T.A., et al. (2002) Factorial Study of the Effects of Atorvastatin and Fish Oil on Dyslipidaemia in Visceral Obesity. European Journal of Clinical Investigation, 32, 429-436.
https://doi.org/10.1046/j.1365-2362.2002.01001.x |
